Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IBM and Swiss Hospital Test New Tool for Diagnosing Cancer

Published: Thursday, October 24, 2013
Last Updated: Thursday, October 24, 2013
Bookmark and Share
The compact and easy-to-use device may help unravel tumor heterogeneity and assist in personalized treatment strategies.

IBM scientists are collaborating with pathologists at the University Hospital Zürich to test a new proto-type tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

A critical step in the diagnosis of cancer is the analysis of a patient's biopsy tissue sample, which sometimes can be as small as a pinhead. Even with such a small sample, pathologists can test for the absence or presence of tumor cells and provide important information pertaining to the course of treatment to doctors.

To analyze samples, pathologists typically stain the tissue sample with liquid reagents. The intensity and distribution of the color stain classify and determine the extent of the disease. While this approach provides insights into the tumor, it is increasingly being realized that significant variations exist within the tumor itself; mapping these variations may help understand the drivers for each tumor, and consequently assist in personalizing treatment strategies.

Based on decades of experience in designing silicon computer chips, IBM scientists have developed an innovative technology called a microfluidic probe which can interact with tissue sections at the micrometer scale to help unravel some of the molecular variations within tumors.

The collaboration between IBM and the University Hospital Zürich puts a strong emphasis on uncovering the heterogeneity of tumors. More specifically, the collaboration focuses on lung cancer, which is one of the most prevalent forms of cancer and has a high mortality rate.

“Pathologists are determined to obtain as much accurate information as possible from markedly small biopsy samples”, said Prof. Dr. Alex Soltermann, a pathologist specializing in lung cancer at the Institute for Surgical Pathology of the University Hospital Zürich. “We hope to introduce new technologies, such as the microfluidic probe, into the clinical molecular pathology diagnostic framework to enable a range of investigations, which were previously thought to be infeasible. If we are successful, the tool will be a driver for personalized medicine, and translate into increased confidence in diagnosis and better detection of predictive cancer markers.”

Privatdozent Dr. Peter Schraml, director of the tissue biobank at the Institute of Surgical Pathology, University Hospital Zürich, said, “In addition to assisting in diagnostics, this tool may provide insight into the biomarker distribution in tumor tissues, which can aid in understanding cancer progression.”

The eight-millimeter-wide, diamond-shaped probe consists in its simplest form of a silicon microfluidic head ending with a small tip bearing two microchannels.

“For about a year we have been testing the probe in our lab, and initial results are very encouraging – we are now developing the technology in the context of important aspects in pathology” said Dr. Govind Kaigala, a scientist at IBM Research – Zurich. “Over the next several months, we will install a prototype device at the hospital and work alongside pathologists.”

The tool which houses the microfluidic probe was recently made significantly more compact and user-friendly and today is roughly the size of a tissue box – it is now at stage where it may assist in studying the distribution of low numbers of cancer cells in biopsied samples.

How does it work?

The probe injects very small volumes of reagents on the tissue surface and then continuously aspirates the reagents to prevent spreading and accumulation. This approach is used to deliver and retrieve reagents locally in selected areas of a tissue section with pinpoint accuracy. This local interaction with the tissue sample helps in mapping the heterogeneity in the tissue.

“We are very excited to partner with IBM on the microfluidic probe technology to develop techniques for its use in the clinical pathology framework – this is a fine example of a translational research that could also help answer some basic science questions” says Prof. Holger Moch, head of the Institute of Surgical Pathology at the University Hospital Zürich.

IBM scientists aspire to eventually partner with a medical equipment manufacturer to license the technology and bring it to market as a tool to assist pathologists in making challenging and critical decisions. The microfluidic probes are designed and manufactured at the Binnig and Rohrer Nanotechnology Center on the campus of IBM Research - Zurich.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IBM and Mars Launch Pioneering Effort to Drive Advances in Global Food Safety
New Sequencing the Food Supply Chain Consortium to undertake the largest-ever metagenomics study and unlock food safety insights across the supply chain.
Friday, February 06, 2015
IBM’s Big Data & Analytics Monitors Babies at INFANT Centre
INFANT Centre at University College Cork to use IBM Big Data & Analytics for real time monitoring of babies in neonatal intensive care.
Tuesday, January 27, 2015
The New York Genome Center and IBM Watson Group Collaborate
Project aims to apply advanced analytics to genomic treatment options for brain cancer patients.
Wednesday, September 10, 2014
Texas A&M System Teams with IBM to Drive Computational Sciences Research through Big Data and Analytics
The collaboration will leverage the power of big data analytics and high performance computing (HPC) systems.
Monday, February 03, 2014
IBM Commits $1.2 Billion to Expand Global Cloud Footprint, Builds Massive Network
IBM is committing to significantly expand its global network of cloud data centers.
Monday, January 27, 2014
IBM’s Biomedical Analytics Platform Helps Doctors Personalise Treatment
Italy’s Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments.
Tuesday, March 20, 2012
New Silicon Probe Assists in Disease Diagnostics and Drug Discovery
Scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately, reducing the need for large biopsy samples.
Monday, January 16, 2012
IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis
New advanced research effort to demonstrate a silicon-based “DNA Transistor” could help pave the way to read human DNA easily.
Thursday, October 08, 2009
IBM and University Researchers to Develop Research Tools to Improve Cancer Patient Outcomes
Advanced imaging and computer technologies aimed at providing for reliable prognosis leading to more personalized treatment.
Wednesday, February 13, 2008
IBM Discovery Could Shed Light on Workings of the Human Genome
IBM researchers discover numerous DNA patterns shared by areas of the human genome.
Wednesday, April 26, 2006
IBM Joins Forces with top Cancer Centers
IBM Collaborates with MSKCC, the Molecular Profiling Institute and Sainte-Justine Research Center.
Friday, November 11, 2005
IBM create smallest solid-state light emitter with Nanotubes

Thursday, May 08, 2003
IBM and IDBS Form Global Strategic Alliance

Wednesday, April 02, 2003
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!